Goldman Sachs’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-63,100
| Closed | -$8.56M | – | 6750 |
|
|
2021
Q1 | $8.56M | Buy |
63,100
+50,000
| +382% | +$6.46M | ﹤0.01% | 2693 |
|
|
2020
Q4 | $1.68M | Buy |
+13,100
| New | +$1.54M | ﹤0.01% | 3846 |
|
|
2018
Q1 | – | Sell |
-40,000
| Closed | -$1.7M | – | 6525 |
|
|
2017
Q4 | $1.7M | Buy |
+40,000
| New | +$1.5M | ﹤0.01% | 3913 |
|
|
2016
Q4 | – | Sell |
-11,900
| Closed | -$431K | – | 7168 |
|
|
2016
Q3 | $431K | Sell |
11,900
-88,100
| -88% | -$2.92M | ﹤0.01% | 5183 |
|
|
2016
Q2 | $3.4M | Sell |
100,000
-95,000
| -49% | -$3.09M | ﹤0.01% | 3171 |
|
|
2016
Q1 | $5.15M | Buy |
195,000
+45,000
| +30% | +$1.31M | ﹤0.01% | 2700 |
|
|
2015
Q4 | $7.31M | Buy |
+150,000
| New | +$5.4M | ﹤0.01% | 2509 |
|
|
2015
Q3 | – | Sell |
-50,000
| Closed | -$1.58M | – | 7567 |
|
|
2015
Q2 | $1.58M | Buy |
+50,000
| New | +$1.61M | ﹤0.01% | 4084 |
|
Goldman Sachs's XLRN Position: Q4 2021 in Review
Goldman Sachs sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 418,302 shares — an estimated $72M sold.
Goldman Sachs first reported a position in XLRN in Q4 2014 and held it in 28 quarters. The position peaked at $72M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Goldman Sachs reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Goldman Sachs sold 418,302 Acceleron Pharma shares in Q4 2021, an estimated $72M.
- Goldman Sachs first reported a position in Acceleron Pharma in Q4 2014 and held it in 28 quarters.
- Goldman Sachs's Acceleron Pharma position peaked at $72M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.